drugset / Trial / NCT02620800
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
Timeline
- Start
- 2016-01-18
- Primary completion
- 2018-10-29
- Completion
- 2018-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Leucovorin | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 180 mg/m2 | Intravenous |